XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: A retrospective study of the anatolian society of medical oncology

Simple item page
dc.contributor.authorDuran A.O.
dc.contributor.authorKaraca H.
dc.contributor.authorBesiroglu M.
dc.contributor.authorBayoglu I.V.
dc.contributor.authorMenekse S.
dc.contributor.authorYapici H.S.
dc.contributor.authorYazilitas D.
dc.contributor.authorBahceci A.
dc.contributor.authorUysal M.
dc.contributor.authorSevinc A.
dc.contributor.authorHacibekiroglu I.
dc.contributor.authorAksoy A.
dc.contributor.authorTanriverdi O.
dc.contributor.authorArpaci E.
dc.contributor.authorInanc M.
dc.contributor.authorDane F.
dc.contributor.authorOzkan M.
dc.date.accessioned2025-04-10T11:12:27Z
dc.date.available2025-04-10T11:12:27Z
dc.date.issued2014
dc.description.abstractBackground: XELOX plus bevacizumab (XELOX-Bev) and FOLFIRI plus Bevacizumab (FOLFIRI - Bev) treatments are an effective strategies patients with metastatic colorectal cancer (mCRC).The aim of this study was to compare efficacy of first-line XELOX-Bev treatment vs FOLFIRI-Bev treatment for mCRC. Materials and Methods: A total of 409 patients with mCRC who received chemotherapy were included and divided into 2 groups. Group 1 (n = 298) received XELOX-Bev and Group 2 (n = 111) FOLFIRI-Bev. Comparisons were made in terms of overall (OS) and progression-free (PFS) survival, response rate (RR), and grade 3-4 toxicity. Results: Median follow-up was 11 months in Group 1 and 15 months for Group 2. Complete remission was observed in 29 (9.7%) and 2 (1.8%) patients, partial remission in 139 (46.6%) and 27 (24.5%) , stable disease in 88 (29.5%) and 49 (44.1%) and progressive disease in 42 (14.1%) and 33 (30.0%) patients in Group 1 and 2, respectively. Median OS was 25 months (range 2-57 months, 95%CI; 22.2-27.7) for Group 1 and 20 months (range 1-67 months, 95%CI; 16.8-23.1) for Group 2 (p = 0.036). Median PFS was 9.6 months (range 2-36 months, 95%CI; 8.8-10.4) for Group 1 and 9 months (range 1-44 months, 95%CI; 7.4-10.5) for Group 2 (p = 0.019). Objective RR was 56.4% in Group 1 and 26.1% in Group 2 (p < 0.001). Conclusions: First-line XELOX-Bev is more effective with a better response rate, prolongation of median PFS/OS, and a superior safety profile compared with FOLFIRI-Bev.
dc.identifier.DOI-ID10.7314/APJCP.2014.15.23.10375
dc.identifier.urihttp://hdl.handle.net/20.500.14701/49618
dc.publisherAsian Pacific Organization for Cancer Prevention
dc.titleXELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: A retrospective study of the anatolian society of medical oncology
dc.typeArticle

Files

Collections

Scopus Koleksiyonu